| 1,410 | 37 | 161 |
| 下载次数 | 被引频次 | 阅读次数 |
阿尔茨海默病(AD)是目前最为常见的一种神经退行性疾病,其病因及发病机制至今还不是很清楚。近几年,越来越多的研究发现,神经炎症在AD的发生发展过程中发挥着重要作用。其中,小胶质细胞的激活及其产生的炎症因子是AD神经炎症的主要表现。此外,在AD疾病过程中,外周侵入脑内的淋巴细胞及炎症因子也参与了AD的神经炎症。因此,研发副作用小的非甾体类抗炎药有望成为防治AD的新靶点。
Abstract：Alzheimer's disease(AD) is the most common neurodegenerative disease,and its etiology and pathogenesis are still not very clear so far.In recent years,a growing number of studies have found that neuroinflammation plays an important role in the development of AD.The activation of microglia and the inflammatory cytokines produced by the cells represent the neuroinflammation in many ways.In addition,peripheral lymphocytes and inflammatory cytokines invading into the brain in AD progress join the neuroinflammation as well.Therefore,the investigation of non-steroidal anti-inflammatory drugs with small side effect may become a new target for prevention and treatment of AD.
[1]Price DL,Tanzi RE,Borchelt DR,et al.Alzheimer’s dis-ease:genetic studies and transgenic models[J].Annu RevGenet,1998,32:461-493.
[2]Halliday G,Robinson SR,Shepherd C,et al.Alzheimer’sdisease and inflammation:a review of cellular and thera-peutic mechanisms[J].Clin Exp Pharmacol Physiol,2000,27(1-2):1-8.
[3]Breitner JC.NSAIDs and Alzheimer’s disease:how far togeneralise from trials[J].Lancet Neurol,2003,2(9):527-527.
[4]Lim GP,Yang F,Chu T,et al.Ibuprofen suppresses plaquepathology and inflammation in a mouse model forAlzheimer’s disease[J].J Neurosci,2000,20(15):5709-5714.
[5]TangYP,Haslam SZ,Conrad SE,et al.Estrogen increasesbrain expression of the mRNA encoding transthyretin,anamyloid beta scavenger protein[J].J Alzheimers Dis,2004,6(4):413-420.
[6]Morgan D,Gordon MN,Tan J,et al.Dynamic complexity ofthe microglial activation response in transgenic models ofamyloid deposition:implications for Alzheimer therapeutics[J].J Neuropathol Exp Neurol,2005,64(9):743-753.
[7]Teeling JL,Perry VH.Systemic infection and in flammationin acute CNS injury and chronic neurodegeneration:un-derlying mechanisms[J].Neuroscience,2009,158(3):1062-1073.
[8]Sheng JG,Zhu SG,Jones RA,et al.Interleukin-1 promotesexpression and phosphorylation of neurofilament and tauproteins in vivo[J].Exp Neurol,2000,163(2):388-391.
[9]Li Y,Liu L,Kang J,et al.Neuronal-glial interactions medi-ated by interleukin-1 enhance neuronal acetylcholines-terase activity and mRNA expression[J].J Neurosci,2000,20(1):149-155.
[10]Sheng JG,Jones RA,Zhou XQ,et al.Interkeukin-1 pro-motion of MAPK-p38 over expression in experimental ani-mals and in Alzheimer’s disease:potential significance fortau protein phosphorylation[J].Neurochem Int,2001,39(5-6):341-348.
[11]Ringheim GE,Szczepanik AM,Petko W,et al.Enhance-ment of beta-amyloid precursor protein transcription andexpression by the soluble interleukin-6 receptor/inter-leukin-6 complex[J].Brain Res Mol Brain Res,1998,55(1):35-44.
[12]Tarkowski E,Blennow K,Wallin A,et al.Intracerebralproduction of rumor necrosis factor-alpha,a local neuro-protective agent,in Alzheimer disease and vascular de-mentia[J].J Clin Immunol,1999,19(4):223-230.
[13]Stalder AK,Carson MJ,Pagenstecher A,et al.Late-onsetchronic inflammatory encephalopathy in immune compe-tent and severe combined immune deficient(SCID)micewith astrocyte targeted expression of tumor necrosis factor[J].Am J Pathol,1998,153(3):767-783.
[14]Grammas P,Ovase R.Cerebrovascular transforming growthfactor-beta contributes to inflammation in the Alzheimer’sdisease brain[J].Am J Pathol,2002,160(5):1583-1587.
[15]马波,张建军.与阿尔茨海默病密切相关的α-、β-、γ-分泌酶的研究进展[J].国外医学药学分册,2005,32(1):22-26.
[16]Cotman CW,Tenner AJ,Cummings BJ.Beta-amyloidconverts an acute phase injury response to chronic in-jury responses[J].Neurobiol Aging,1996,17(5):723-731.
[17]Christie RH,Freeman M,Hyman BT.Expression of themacrophage scavenger receptor,a multifunctional lipopro-tein receptor,in microglia associated with senile plaquesin Alzheimer’s disease[J].Am J Pathol,1996,148(2):399-403.
[18]Lue LF,Walker DG,Brachova L,et al.Involvement of mi-croglial receptor for advanced glycation endproducts(RAGE)in Alzheimer’s disease:identifcation of a cellularactivation mechanism[J].Exp Neurol,2001,171(1):29-45.
[19]Hickey WF,Hsu BL,Kimura H.T-lymphocyte entry intothe central nervous system[J].J Neurosci Res,1991,28(2):254-260.
[20]Hickey WF.Leukocyte traffic in the central nervous sys-tem:the participants and their roles[J].Semin Immunol,1999,11(2):125-137.
[21]Dietrich JB.The adhesion molecule ICAM-1 and its regu-lation in relation with the blood-brain barrier[J].J Neu-roimmunol,2002,128(1-2):58-68.
[22]Mayhan WG.Cellular mechanisms by which tumor necro-sis factor-alpha produces disruption of the blood-brainbarrier[J].Brain Res,2002,927(2):144-152.
[23]Wong D,Prameya R,Dorovini-Zis K.In vitro adhesionand migration of T lymphocytes across monolayers ofhuman brain microvessel endothelial cells:regulation by I-CAM-1,VCAM-1,E-selectin and PECAM-1[J].J Neu-ropathol Exp Neurol,1999,58(2):138-152.
[24]McCarron RM,Wang L,Racke MK,et al.Cytokine-regu-lated adhesion between encephalitogenic T lymphocytesand cerebrovascular endothelial cells[J].J Neuroimmunol,1993,43(1-2):23-30.
[25]Farkas IG,Czigner A,Farkas E,et al.Beta-amyloid pep-tide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain[J].Acta Histochem,2003,105(2):115-125.
[26]Azab NA,Bassyouni IH,Emad Y,et al.CD4+CD25+regulatory T cells(TREG)in systemic lupus erythemato-sus(SLE)patients:the possible influence of treatment withcorticosteroids[J].Clin Immunol,2008,127(2):151-157.
[27]Bouchliou I,Miltiades P,Nakou E,et al.Th17 and Foxp3(+)T regulatory cell dynamics and distribution in myelo-dys-plastic syndromes[J].Clin Immunol,2011,139(3):350-359.
[28]Reynolds AD,Banerjee R,Liu J,et al.Neuroprotectiveactivities of CD4+CD25+regulatory T cells in an animalmodel of Parkinson’s disease[J].J Leukoc Biol,2007,82(5):1083-1094.
[29]Kebir H,Kreymborg K,Ifergan I,et al.Human TH17lymphocytes promote blood-brain barrier disruption andcentral nervous system inflammation[J].Nat Med,2007,13(10):1173-1175.
[30]Saresella M,Calabrese E,Marventano I,et al.Increasedactivity of Th-17 and Th-9 lymphocytes and a skewing ofthe post-thymic differentiation pathway are seen inAlzheimer’s disease[J].Brain Behav Immun,2011,25(3):539-547.
[31]Dantzer R,Konsman JP,Bluthe RM,et al.Neural andhumoral pathways of communication from the immune sys-tem to the brain:parallel or convergent[J].Auton Neurosci,2000,85(1-3):60-65.
[32]Miller AJ,Luheshi GN,Rothwell NJ,et al.Local cytokineinduction by LPS in the rat air pouch and its relationshipto the febrile response[J].Am J Physiol,1997,272(3 pt2):R857-861.
[33]Breitner JC,Welsh KA,Helms MJ,et al.Delayed onset ofAlzheimer’s disease with nonsteroidal anti-inflammatoryand histamine H2 blocking drugs[J].Neurobiol Aging,1995,16(4):523-530.
[34]Szekely CA,Town T,Zandi PP.NSAIDs for the chemo-prevention of Alzheimer’s disease[J].Subcell Biochem.2007,42:229-248.
[35]Giovannini MG,Scali C,Prosperi C,et al.Beta-amyloid-induced inflammation and cholinergic hypofunction in therat brain in vivo:involvement of the p38MAPK pathway[J].Neurobiol Dis,2002,11(2):257-274.
[36]Lleo A,Galea E,Sastre M.Molecular targets of non-steroidalanti-inflammatory drugs in neurodegenerative diseases[J].Cell Mol Life Sci,2007,64(11):1403-1418.
[37]Lleo A,Berezovska O,Herl L,et al.Nonsteroidal anti-in-flammatory drugs lower Abeta42 and change presenilin 1conformation[J].Nat Med,2004,10(10):1065-1066.
[38]Veld BA,Ruitenberg A,Hofman A,et al.Nonsteroidalantiinflammatory drugs and the risk of Alzheimer’s dis-ease[J].N Engl J Med,2001,345(21):1515-1521.
[39]Szekely CA,Breitner JC,Fitzpatrick AL,et al.NSAID useand dementia risk in the Cardiovascular Health Study:roleof APOE and NSAID type[J].Neurology,2008,70(1):17-24.
基本信息:
中图分类号:R749.16
引用信息:
[1]张军,柯开富,邱一华,等.神经炎症在阿尔茨海默病发病机制中的作用[J].南通大学学报(医学版),2012,32(01):44-47.
基金信息:
国家自然科学基金资助项目(30870819)